NCT07332000 2026-03-17
A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec
Candel Therapeutics, Inc.
Phase 2 Recruiting
Clinical Trials
12 trialsNCT00492050 2026-03-11
Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05536349 2026-02-24
Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07363031 2026-01-23
Oral Herpesviruses and Oral Mucositis in Patients Receiving Head and Neck Radiotherapy
Instituto Oncoclinicas
Phase 2 Enrolling by invitation
NCT02768363 2025-07-30
Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)
Candel Therapeutics, Inc.
Phase 2 Active not recruiting
NCT03004183 2024-10-15
STOMP
The Methodist Hospital Research Institute
Phase 2 Completed
NCT00589875 2024-04-03
BrTK02
Candel Therapeutics, Inc.
Phase 2 Completed
NCT02831933 2023-09-21
ENSIGN
The Methodist Hospital Research Institute
Phase 2 Terminated
NCT01972035 2022-04-12
ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation
University of Minnesota
Phase 2 Completed
NCT03541928 2021-04-06
Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery
The Methodist Hospital Research Institute
Phase 2 Unknown
NCT00042328 2015-08-24
A Pharmacokinetic Study of Valacyclovir in Pediatric Oncology Patients
Baylor College of Medicine
Phase 2 Completed
NCT00562770 2012-07-31
Oral Valganciclovir Versus Valacyclovir
M.D. Anderson Cancer Center
Phase 2 Completed